Purpose: We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD).
Methods: The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5±1.8 mono-injections of bevacizumab (1.5mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5mg) and triamcinolone acetonide (about 20mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2-3months after the intervention.
Results: Visual acuity improved significantly (p=0.03) from 0.80±0.40 logMAR prior to the combined injection to 0.65±0.42 logMAR at 3 months after the injection. An improvement of ≥1Snellen line was found in eight subjects, an increase of ≥2lines in five subjects, and an improvement of ≥3lines in two subjects. One patient lost 1line and one patient lost 3lines. Central retinal thickness decreased significantly from 272±62μm to 220±47μm (p=0.03). At the 6-month follow-up examination, central retinal thickness had increased again to 319±142μm, which was not significantly (p=0.30) different from baseline measurements.
Conclusions: The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono-injections have failed to improve vision and reduce macular oedema.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-3768.2008.01502.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis.
Clin Ophthalmol
January 2025
2nd Department of Ophthalmology, Medical School of University of Athens, "attikon" University Hospital, Athens, Greece.
Purpose: To evaluate the 2-year outcomes of resveratrol oral supplement given as an adjunctive treatment in patients with wet age-related macular degeneration (AMD) that were treated with intravitreal injections of aflibercept.
Patients And Methods: In our retrospective study, 50 treatment-naïve patients suffering from wet-AMD were included. They were assigned to two subgroups of 25 patients each.
A Phytopathogen Associated with Human Ocular Infections-A Case Report of Endophthalmitis and Systematic Review of Human Infections.
J Clin Med
January 2025
Department of Clinical Microbiology, General Hospital "G. Gennimatas", 11527 Athens, Greece.
: is an important phytopathogenic fungus affecting over 500 plant species worldwide. However, this fungus rarely causes disease in humans. : We reported the first case of endophthalmitis due to , describing microbiological diagnostic approaches.
View Article and Find Full Text PDFComparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis.
Int J Mol Sci
January 2025
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke-shi 329-0498, Tochigi, Japan.
Aflibercept and brolucizumab, two anti-VEGF agents used as intravitreal injections in ophthalmology, differ significantly in molecular weight (aflibercept-115 kDa and brolucizumab-26 kDa). Using aqueous humor samples collected after drug administration, we measured and performed a comparative analysis of pharmacokinetics and half-lives of these drugs in the human eye. Since the quantification of monoclonal antibodies (mAbs) using antigen-antibody reactions, such as ELISA, is influenced by endogenous ligands or anti-drug antibodies, we employed nano-surface and molecular-orientation limited proteolysis (nSMOL), combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS), for accurate measurements.
View Article and Find Full Text PDFInnovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.
BMC Ophthalmol
January 2025
Department of Vitreoretina, Akhand Jyoti Eye Hospital, Mastichak, Saran, Bihar, India.
Purpose: To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (CF).
Methods: Treatment naïve neovascular age related macular degeneration (n-AMD) patients with SMH were retrospectively analyzed. Patients received either innovator or biosimilar RBZ (3 loading doses followed by pro re nata regimen) and single injection of intravitreal CF.
Improving ROP management: insights from a comparative analysis of screening and treatment modalities in a tertiary hospital, Pakistan.
BMC Ophthalmol
January 2025
Institute of Ophthalmolohy, King Edward Medical University, Lahore, Pakistan.
Background: The principal objective of our study is to evaluate the characteristics of babies with type 1 ROP, screening practices and treatment trends in a tertiary care centre in Pakistan.
Methods: This prospective study at Mayo Hospital, Lahore (July 2022-July 2024), included 89 preterm infants with type 1 ROP, selected using non-probability sampling. Infants were categorized based on international (GA < 32weeks or BW < 1500 g) and local screening criteria (GA < 35 weeks or BW < 2000 g), and treatment outcomes were evaluated across three groups: Anti-VEGF, combination therapy (Anti-VEGF followed by laser), and laser therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!